Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 15/20 | 0.63 |
| ▸ | ESR2 | Q92731 | 9/20 | 0.63 |
| ▸ | AR | P10275 | 5/20 | 0.50 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | EGFR | P00533 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | FYN | P06241 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | APEX1 | P27695 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25596207 | 0.84 | ESR1 (0.59) | ESR1ESR2ARPDE10ATDP1 | |
| SCHEMBL15471624 | 0.83 | ESR1 (0.54) | ESR1ESR2ARTDP1KDM4E | |
| SCHEMBL2600039 | 0.83 | ALOX15 (0.59) | ESR1ARTDP1TP53KDM4E | |
| SCHEMBL9007994 | 0.80 | ESR1 (0.59) | ESR1ESR2ARPDE10ATDP1 | |
| SCHEMBL13205236 | 0.80 | ESR1 (0.59) | ESR1ESR2ARPDE10ATDP1 | |
| SCHEMBL10711420 | 0.79 | ESR1 (0.54) | ESR1ESR2TDP1KDM4EMEN1 | |
| SCHEMBL339012 | 0.78 | ESR1 (0.58) | ESR1ESR2ARTDP1TP53 | |
| SCHEMBL29499835 | 0.78 | ESR1 (0.56) | ESR1ESR2AR | |
| SCHEMBL3234644 | 0.78 | ESR1 (0.68) | ESR1ESR2AR | |
| SCHEMBL25596190 | 0.78 | ESR1 (0.52) | ESR1ESR2ARPDE10ATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11078233-B2 | Tripeptide epoxy ketone protease inhibitors | ONYX THERAPEUTICS, INC. (US) | 2021-08-03 | — | — | US | disclosed |
| US-20200207809-A1 | TRIPEPTIDE EPOXY KETONE PROTEASE INHIBITORS | ONYX THERAPEUTICS, INC. | 2020-07-02 | — | — | US | disclosed |
| US-RE47302-E1 | Peptide epoxyketone immunoproteasome inhibitors | ONYX THERAPEUTICS INC. (US) | 2019-03-19 | — | — | US | disclosed |
| US-20160368946-A1 | TRIPEPTIDE EPOXY KETONE PROTEASE INHIBITORS | ONYX THERAPEUTICS, INC. | 2016-12-22 | — | — | US | disclosed |
| US-9434761-B2 | Tripeptide epoxy ketone protease inhibitors | ONYX THERAPEUTICS, INC. (US) | 2016-09-06 | — | — | US | disclosed |
| US-20140336106-A1 | TRIPEPTIDE EPOXY KETONE PROTEASE INHIBITORS | ONYX THERAPEUTICS, INC. (US) | 2014-11-13 | — | — | US | disclosed |
| US-20130150376-A1 | Novel Sultam Compounds | PFIZER INC. (US) | 2013-06-13 | — | — | US | disclosed |
| US-20110046160-A1 | Novel Class of Spiro Piperidines for the Treatment of Neurodegenerative Diseases | PFIZER, INC. | 2011-02-24 | — | — | US | disclosed |
| EP-0650952-B1 | Process for 3,5-di-tert-butylsalicylaldehyde | SEPRACOR INC (US) | 1998-02-18 | — | — | EP | disclosed |
| EP-0650952-A1 | Process for 3,5-di-tert-butylsalicylaldehyde | SEPRACOR, INC. (US) | 1995-05-03 | — | — | EP | disclosed |
| US-5324860-A | Process for 3,5-di-tert-butylsalicylaldehyde | SEPRACOR, INC. (US) | 1994-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11078233-B2 | Tripeptide epoxy ketone protease inhibitors | PREP, CTRL, ENPEP | ESR1 874/4885ESR2 523/4885AR 2777/4885 |
| US-20200207809-A1 | TRIPEPTIDE EPOXY KETONE PROTEASE INHIBITORS | PREP, CTRL, ENPEP | ESR1 874/4885ESR2 523/4885AR 2777/4885 |
| US-20160368946-A1 | TRIPEPTIDE EPOXY KETONE PROTEASE INHIBITORS | PREP, CTRL, ENPEP | ESR1 874/4885ESR2 523/4885AR 2777/4885 |
| US-20140336106-A1 | TRIPEPTIDE EPOXY KETONE PROTEASE INHIBITORS | PREP, CTRL, ENPEP | ESR1 874/4885ESR2 523/4885AR 2777/4885 |
| US-20130150376-A1 | Novel Sultam Compounds | SULT2A1, SULT1A1, SULT1E1 | ESR1 2893/4885ESR2 1460/4885AR 1495/4885 |
| US-20110046160-A1 | Novel Class of Spiro Piperidines for the Treatment of Neurodegenerative Diseases | SNCA, PARK7, HTT | ESR1 3479/4885ESR2 1757/4885AR 1123/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.